A new study associated with Immorta Bio suggests that combining a senolytic vaccine with mesenchymal stem cells might create a synergistic impact. However, the findings rest on acute, artificially induced injury models rather than natural aging [1].
Clearing out senescent cells to help stem cells work
Mesenchymal stem cell (MSC) therapies have largely underperformed in the clinic. MSCs are connective-tissue stem cells that help mostly not by becoming new tissue but by secreting repair-promoting factors. Despite strong preclinical promise, clinical MSC trials in fibrosis, inflammation, and organ failure have shown only modest benefits [2].







